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Allogeneic hematopoietic stem cell transplantation for patients with a hemoglobinopathy can be curative but
is limited by donor availability. Although positive results are frequently observed in those with an HLA-
matched sibling donor, use of unrelated donors has been complicated by poor engraftment, excessive
regimen-related toxicity, and graft-versus-host disease (GVHD). As a potential strategy to address these
obstacles, a pilot study was designed that incorporated both a reduced-intensity conditioning and mesen-
chymal stromal cells (MSCs). Six patients were enrolled, including 4 with high-risk sickle cell disease (SCD)
and 2 with transfusion-dependent thalassemia major. Conditioning consisted of ﬂudarabine (150 mg/m2),
melphalan (140 mg/m2), and alemtuzumab (60 mg for patients weighing > 30 kg and .9 mg/kg for patients
weighing <30 kg). Two patients received HLA 7/8 allele matched bone marrow and 4 received 4-5/6 HLA
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Umbilical cord
Bone marrow
Engraftment
Graft-versus-host diseasematched umbilical cord blood as the source of HSCs. MSCs were of bone marrow origin and derived from a
parent in 1 patient and from an unrelated third-party donor in the remaining 5 patients. GVHD prophylaxis
consisted of cyclosporine A and mycophenolate mofetil. One patient had neutropenic graft failure, 2 had
autologous hematopoietic recovery, and 3 had hematopoietic recovery with complete chimerism. The 2 SCD
patients with autologous hematopoietic recovery are alive. The remaining 4 died either from opportunistic
infection, GVHD, or intracranial hemorrhage. Although no infusion-related toxicity was seen, the cotrans-
plantation of MSCs was not sufﬁcient for reliable engraftment in patients with advanced hemoglobinopathy.
Although poor engraftment has been observed in nearly all such trials to date in this patient population, there
was no evidence to suggest that MSCs had any positive impact on engraftment. Because of the lack of
improved engraftment and unacceptably high transplant-related mortality, the study was prematurely
terminated. Further investigations into understanding the mechanisms of graft resistance and development
of strategies to overcome this barrier are needed to move this ﬁeld forward.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) is the onlycurative therapy for sickle cell disease (SCD)
and thalassemia [1,2]. However, most experience with this
treatment modality is in patients who have an HLA-matched
sibling donor after myeloablative conditioning, such as
busulfan, cyclophosphamide, and antithymocyte globulin [3].
These studies established the proof of concept that ablation of
host hematopoiesis and immunity could allow durable
engraftment. In those with matched sibling donors, the
overall probability of cure has been consistently in the 80% to
85% range, with less than 10% treatment-related mortality
[2,4e12]. Importantly, stabilization or reversal of organ
damage from SCD has been documented [7]. However, most
patients do not have an HLA-matched sibling donor and are
rarely considered for allogeneic HSCT because of the difﬁculty
in ﬁnding a suitably HLA-matched unrelated donor. More-
over, conventional myeloablative conditioning regimens are
often associatedwith a high risk of early death from regimen-
related side effects as well as from late effects, such as infer-
tility [13]. Use of partially HLA-matched donors is associated
with increased risks of graft failure, acute and chronic graft-
versus-host disease (GVHD), and slow immune recovery
with consequent high risks of opportunistic infection.
One approach to decrease transplant-related mortality
is to decrease the intensity of the conditioning regimen.
Although effective in patients with malignant disease, non-
myeloablative conditioning regimens have typically failed
to ensure a high rate of engraftment in patients with a he-
moglobinopathy [14]. Higher dose but reduced-intensity
conditioning (RIC) regimens have met with limited success
[15e18], at least in the context of HLA-matched marrow or
mobilized peripheral blood from unrelated donors.
The lack of a suitable HLA-matched donor has been a
major limitation in the ﬁeld because most patients with
hemoglobinopathies are of non-European decent. For this
reason, HLA-mismatched umbilical cord blood (UCB) has
been explored as a graft source. Although there appears to be
lower stringency for the degree of HLA match, UCB is asso-
ciated with a higher rate of graft failure, particularly in
patients with nonmalignant diseases [19,20]. Although the
use of haploidentical donors is emerging, early reports also
suggest it is associated with a high rate of graft failure/
autologous recovery in this setting [21e23].
In an attempt to address the engraftment barrier, we
proposed the cotransplantation of mesenchymal stromal
cells (MSCs) to facilitate engraftment of unrelated donor
HSCs. MSCs are multipotential, nonhematopoietic progenitor
cells capable of differentiating into various lineages [24e28],but they also support the expansion of HSC progenitors
in vitro and engraftment inmurinemodels in vivo. Therefore,
we hypothesized that MSCs might enhance hematopoietic
recovery after RIC in patients with hemoglobinopathy
[29e31]. Herein, we report the results of a prospective pilot
study designed to explore the use of bone marrowederived
MSCs as a strategy to enhance the engraftment of unrelated
donor marroweor UCB-derived HSCs in the context of a RIC
regimen in patients with hemoglobinopathies lacking a HLA
matched sibling donor.METHODS
Patient Characteristics
Patients were enrolled at 3 institutions, Stanford University, University
of Minnesota, and University of Alabama at Birmingham. The institutional
review boards of each institution approved the study. The Institutional Re-
view Board at the National MarrowDonor Program also approved the study.
The trial was registered in the clinical trials network as NCT00957931.
All patients underwent allogeneic HSCT between 2009 and 2011. Four
patients had an underlying diagnosis of homozygous SCD, and 2 patients
had transfusion-dependent thalassemia major. None of the patients had an
HLA-matched sibling donor available. Median patient age was 10 years
(range, 8 to 18 years). Indications for HSCT are shown in Table 1, and patient
characteristics are shown in Table 2.Conditioning Regimen and GVHD Prophylaxis
Conditioning was a reduced intensity regimen that consisted of alem-
tuzumab administered on days 21 through 19, ﬂudarabine on days 7
through 3, and melphalan on days 2 and 1. Alemtuzumab was given as
3 daily doses of 10, 20, and 30 mg to patients weighing >30 kg and at a dose
of .3 mg/kg for patients weighing <30 kg. Fludarabine was administered at
30 mg/m2 per dose for a total of 150 mg/m2, and melphalan was adminis-
tered at 70 mg/m2 per dose for a total dose of 140 mg/m2. GVHD prophylaxis
consisted of cyclosporine A and mycophenolate mofetil. Both drugs were
started on day 2 with plan to continue cyclosporine A for 6 months and
mycophenolate mofetil for 100 days before initiating taper.Stem Cell Sources
The HSC source was bone marrow in 2 patients, a single UCB graft in
1 patient, and a double UCB graft in 3 patients. UCB units were 4-5/6 HLA
matched to the recipients at the antigen level for HLA-A and -B and allele
level for HLA-DRB1, whereasmarrow donors were 7/8 HLAmatched at allele
level for HLA-A, -B, -C, and -DRB1. The criteria for selecting UCB units
changed to the following after patient 1, who received a single 4/6 HLA-
matched UCB, failed to engraft. Only 5-6/6 HLA-matched single units were
allowed and only if they met the following cell dose criteria: 5  107/kg
total nucleated cells for 5/6 matched UCB and 4  107/kg total nucleated
cells for 6/6 matched UCB units. If no single UCB unit with the above-
mentioned cell dose and HLA-matching criteria was available, 2 UCB units
were selected for transplant. Criteria for double UCB units included units
that were 4-6/6 HLA matched to the patient as well as to each other irre-
spective of the locus of mismatch. Cell dose criteria for double UCB units
included a minimum combined total dose of at least 4  107/kg total
nucleated cells with each unit having a minimum dose of 1.5  107/kg total
nucleated cells.
Table 1
Indications for HSCT
Patient
No.
Disease Indication for HSCT No. of
Known
Transfusions
before HSCT
1 SCD Recurrent episodes of acute chest
syndrome, lung disease with
oxygen requirement at night,
failure of hydroxyurea therapy
20
2 SCD Recurrent episodes of severe
acute chest syndrome, 2-3
episodes of priapism/year,
multiple vaso-occlusive crises,
restrictive lung disease with
small airway obstruction, 3
episodes of splenic sequestration
21
3 b-Thalassemia Transfusion dependent,
intolerance to chelator therapy;
iron overload in liver with 7.1 mg
iron/g dry liver tissue by liver
MRI
84
4 SCD Major cerebrovascular accident
with neurologic sequelae,
abnormal MRA of brain with
signiﬁcant intracranial arterial
disease, most severely involving
the left MCA territory, with high-
grade arterial stenosis and
occlusions; mild restrictive
defects in PFTs; iron overload
with 8mg/g iron in liver detected
by liver MRI
74
5 b-Thalassemia Transfusion dependent, severe
iron overload in multiple organs
(t2* scan), on chelation with 2
agents, cardiac dysfunction
secondary to iron overload
220
6 SCD Multiple vaso-occlusive crises
with frequent hospitalizations,
abnormal transcranial Doppler
with increased right-sided
velocities
4
MRI indicates magnetic resonance imaging; MRA, magnetic resonance
angiogram; MCA, middle cerebral artery; PFT, pulmonary function test.
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status following US Food and Drug Administration review. For the ﬁrst pa-
tient enrolled on the study, MSCs were derived from a haploidentical parent;
all other patients received MSCs from a healthy, unmatched third-party
donor. MSC donors (third party and haploidentical) were cytomegalovirus
(CMV) seronegative. The University of Minnesota Molecular and Cellular
Therapeutics Facility performed cell processing under the National Heart,
Lung and Blood Institute’s Production Assistance for Cell Therapy Program
(Principle Investigator, J.E.W.). Brieﬂy, after enrichment of the marrow
mononuclear cells by Ficoll density gradient (Ficoll Hypaque, GE Healthcare,
Pittsburgh, PA), cells were seeded at 1.0 to 1.5  105 cells/cm2 at a media
depth of 1.6 mm in an appropriately sized T-ﬂask and placed in a 5% CO2/Table 2
Patient Characteristics
Patient No. Age/Sex Diagnosis Stem Cell Donor HLA Match
1 8 y/M SCD Single UCB 4/6
2 12 y/M SCD Bone marrow 7/8 (B allele mm)
3 10 y/M Thalassemia major Double UCB 4/6 (both)
4 10 y/M SCD Bone marrow 7/8 (A allele mm)
5 18 y/M Thalassemia major Double UCB 4/6 and 5/6
6 8 y/F SCD Double UCB 4/6 (both)
TNC indicates total nucleated cells.37C incubator. Media consisted of alpha-MEM (Life Technologies, Grand
Island, NY), 16.5% FBS (Hyclone/Thermo Scientiﬁc, Rockford, IL), and
GlutaMax (1% 200 mM; Life Technologies). On days 1 and 2, nonadherent
cells were removed. Media exchanges took place every 2 to 4 days until 70%
to 80% conﬂuence (7 to 10 days). Cells were washed, detached, and inocu-
lated into a cell factory at 40 to 50 cells/cm2. Media was exchanged every 2
to 4 days over the next 7 to 12 days. At 90% conﬂuence, cells were har-
vested, washed, resuspended in 5% human serum albumin (Buminate,
Baxter, Deerﬁeld, IL) at 2 to 20  106 cells/mL, and cryopreserved using
Plasmalyte A (Baxter), DMSO (ﬁnal concentration 10%; Bioniche Pharma,
Morgantown, WV), and human serum albumin (10%; Baxter).
Quality control and lot release testing included infectious disease
markers for relevant communicable diseases, sterility, mycoplasma, endo-
toxin, karyotype (G-banding), ﬂow cytometry (immunophenotype and
viability) [32], and trilineage differentiation [32]. As previously published,
MSC lot release included CD105 and CD90  85% [32], CD45 and HLA-
DR  15%, viability (prefreeze)  70% by 7-amino-actinomycin, endotoxin <
5.0 EU/mL, sterility cultures ¼ no growth, cytogenetics without clonal ab-
normality, and Mycoplasma points to consider negative. For our patients,
MSCs were 95% CD105 and 98% CD90 positive and were 1% CD45 and HLA-
DR; prefreeze viability was 90% by 7-amino-actinomycin staining, endotoxin
levels were <1.0 EU/mL, and aerobic/anaerobic/fungal cultures showed no
growth. Mycoplasma testing (Points to Consider) was negative, and cyto-
genetics (G-banding) showed normal female karyotype. MSC had trilineage
potential in vitro based on special stains for oil red O (adipose tissue), von
Kossa (osteogenic tissue), and toluidine blue (chondrogenic tissue).
On days 0 (4 hours after HSC infusion) and 2, MSCs were thawed at the
bedside for immediate administration and infused. Patients were pre-
medicated with 15 mg/kg acetaminophen and .5 to 1 mg/kg diphenhydra-
mine orally. Vital signs were checked 1 hour and 15 minutes before MSC
infusion and 15 minutes, 30 minutes, 60 minutes, 2 hours, and 4 hours after
infusion. O2 saturation was monitored for the duration of the infusion and
until 9 hours after infusion.
Supportive Care
Supportive care guidelines followed institutional standards. All UCB
patients received granulocyte colony-stimulating factor in the immediate
post-HSCT period. All patients were monitored for infections as per insti-
tutional supportive care guidelines. Antimicrobial prophylaxis included
acyclovir with weekly viral surveillance, including monitoring for CMV and
human herpesvirus 6 (HHV-6), and trimethoprim-sulfamethoxazole or
pentamidine for Pneumocystis jiroveci pneumonia prophylaxis as per insti-
tutional guidelines. For patient 5, who was seropositive for toxoplasma
before transplant, a weekly monitoring by PCR was put in place with the
plan to resume trimethoprim-sulfamethoxazole for prophylaxis after
engraftment. Transfusion parameters were 10 g/dL for hemoglobin and
50,000 for platelets for SCD patients and 8 g/dL for hemoglobin and 10,000
for platelets for thalassemic patients. Additionally, SCD patients received
antiseizure prophylaxis with phenytoin or levetiracetam.
Endpoints/Statistical Evaluation
The primary endpoint of the study was attainment of stable engraft-
ment. Neutrophil engraftment was deﬁned as the ﬁrst of 3 consecutive days
with an absolute neutrophil count > 500/mL, and platelet recovery was
deﬁned as the ﬁrst of 7 consecutive days of a platelet count 50,000/mL
without transfusion. In addition, donor engraftment was determined by
demonstrating chimerism by short tandem repeat analysis in patients’ bone
marrow and/or peripheral blood. Lineage-speciﬁc chimerism analysis was
done by using CD3 for T cell, CD15 for myeloid, CD19 for B cell, and CD34 forHSC Graft Characteristics
(dose/kg body weight)
MSC Graft Characteristics
(dose/kg body weight)
TNC (107) CD34þ (106) CD3þ (107) Day 0 (106) Day 2 (106)
4.8 .5 2.5 2.0 2.0
58.6 4.4 4.5 1.72 1.9
Unit 1: 4.6 Unit 1: .36 Unit 1: 1.8 2.0 2.0
Unit 2: 2.9 Unit 2: .31 Unit 2: 1.1
52.4 7.2 n/a 2.0 2.0
Unit 1: 2.7 Unit 1: .15 Unit 1: .6 1.8 1.5
Unit 2: 2.4 Unit 2: .29 Unit 2: .48
Unit 1: 3.9 Unit 1: .19 Unit 1: .34 2.97 2.97
Unit 2: 2.25 Unit 2: .14 Unit 2: .49
Table 3
Results of Neutrophil and Platelet Engraftment, Outcomes, Complications, and Causes of Death
Patient
No.
Age/
Sex
Diagnosis Stem
Cell
Donor
HLA
Match
Day of Recovery Severity
of Acute
GVHD
Outcome Complications Cause of Death
ANC
>500/mL
Platelets
>50,000/mL
1 8 y/M SCD UCB 4/6 Day þ15 Day þ37 None Alive, with
autoreconstitution
HHV-6 viremia
Graft failure with autologous
recovery
n/a
2 12 y/M SCD BM 7/8 Day þ10 Day þ25 Grade III Death, day þ141 PRES
Intracranial hemorrhage
Grade III acute GVHD
EBV-PTLD
Steroid-
refractory
GVHD
3 10 y/M Thalassemia
major
dUCB 4/6 and 4/6 Not
achieved
Not
achieved
Grade II Death, day þ24 Intracranial bleeding
Grade II GVHD
CMV viremia
Intracranial bleed
4 10 y/M SCD BM 7/8 Day þ9 Not
achieved
None Death, day þ43 CMV pneumonitis CMV
pneumonitis
5 18 y/M Thalassemia
major
dUCB 4/6 and 5/6 Day þ33 Not
achieved
None Death, day þ59 Gram-negative septic shock
Klebsiella and enterobacter
SOS
CMV reactivation
Disseminated toxoplasmosis
Disseminated
toxoplasmosis
6 8 y/F SCD dUCB 4/6 and 4/6 Day þ34 Day þ56 None Alive, with
autoreconstitution
CMV viremia
Adenovirus reactivation
BK virus reactivation
Klebsiella bacteremia
Graft failure with
autologous recovery
n/a
BM indicates blood marrow; ANC, absolute neutrophil count; PRES, posterior reversible encephalopathy syndrome; PTLD, post-transplant lymphoproliferative
disease; EBV, Epstein-Barr virus; dUCB, double UCB; SOS, sinusoidal obstruction syndrome; BK, BK virus; n/a, not applicable.
In patient 3, peripheral blood chimerism showed 100% donor engraftment but ANC >500 was not achieved in blood.
S. Kharbanda et al. / Biol Blood Marrow Transplant 20 (2014) 577e592584stem cell chimerism. Because MSCs were derived from third-party donors,
short tandem repeat analysis was used to determineMSC chimerism as well.
Simon’s optimal 2-stage designwas used for statistical considerations of
this pilot study [33]. The planned enrollment for the ﬁrst stage of the study
was 9. Stopping rules of the study included an unacceptable engraftment
rate of 6 or fewer engraftments in the ﬁrst stage and a 20% incidence of
unexpected grade 3 or higher toxicities or30% treatment-relatedmortality
from expected or unexpected causes in the ﬁrst 100 days after HSCT.RESULTS
Engraftment/Chimerism
Table 3 depicts engraftment results. Three of 6 patients
achieved an absolute neutrophil count 500 on days 10
(patient 2), 9 (patient 4), and 33 (patient 5). Patient 3
demonstrated complete donor chimerism but without
neutrophil recovery at the time of his death on day þ24. His
WBC count on the day of death was 500/mL. The remaining 2
patients (patients 1 and 6) with SCD had autologous he-
matopoietic recovery. Patient 1 had autologous neutrophil
recovery on day 15 with HHV-6 viremia with high fevers
documented on day 18. Patient 6 developed CMV viremia
with high fever and rash at day 10 after HSCT with autolo-
gous reconstitution at day 34. Both patients had received
UCB grafts, including 1 who had received a double UCB graft
(patient 6).
Platelet engraftment was not attained in 3 patients before
death. MSC engraftment was not demonstrated in marrow
aspirates in any of the 6 patients. The presence of donor-
speciﬁc antibodies was reviewed in this patient population
and was found in 3 patients, all of whom were double UCB
recipients. Two of these patients had engrafted, and in pa-
tient 6, who did not engraft, a weak donor-speciﬁc antibody
with a mean ﬂuorescence index of 503 was found against an
HLA-C locus of 1 of the cord blood units. The HLA type of the
third-party MSC donor was also reviewed, and no donor-
speciﬁc antibodies were found against the HLA antigens of
the MSC donor in the nonengrafting patients.Graft-versus-Host Disease
Acute GVHD was observed in 2 of 3 engrafted patients.
Patient 3 developed grade II GVHD that responded to sys-
temic and topical steroids. Patient 2 developed grade III
GVHD of the gastrointestinal tract, which was steroid resis-
tant. Hewas treatedwith inﬂiximab as a second-line agent as
well as additional available doses of third-party MSCs with
doses ranging from 1.79 to 2.44  106/kg on days 23, 44, 47,
and 74 to treat GVHD, but without signiﬁcant response.
Regimen-Related Toxicities
There were no infusion-related toxicities associated with
the MSCs. However, signiﬁcant regimen-related toxicities
unrelated to the MSC infusion were observed (Table 3). Pa-
tient 5, who had a history of severe iron overload, developed
severe sinusoidal obstruction syndrome andwas successfully
treated with deﬁbrotide. Patient 3 with thalassemia had
grade 5 intracranial hemorrhage on day þ11. All 6 patients
developed opportunistic infections (Table 3). CMV reac-
tivation occurred in 4 patients (patients 3, 4, 5, and 6),
patient 6 developed reactivation of BK virus and adenovirus
in addition to CMV, and patients 1 and 2 developed reac-
tivation of HHV-6 and Epstein-Barr virus, respectively.
Patient 2 developed post-transplant Epstein-Barr virus
lymphoproliferative disease. CMV pneumonitis and dissem-
inated toxoplasmosis were the causes of death in 2 patients.
Survival
Only 2 of 6 patients survived, both with SCD and autol-
ogous hematopoietic recovery. Because of the lack of
consistent donor-derived engraftment and excessive mor-
tality, the study was terminated.
DISCUSSION
These results suggest that the strategy of cotransplanta-
tion of allogeneic MSCs did not enhance the engraftment of
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binopathy in the context of the RIC regimen used in this
study. Although it is possible that a fully myeloablative
conditioning is required, particularly in patients who do not
have an HLA-matched donor, previous alloimmunization
secondary to prior transfusions is likely a formidable barrier
to successful engraftment. Although the impact of donor-
speciﬁc anti-HLA antibodies was not known at the time of
this study, it is possible that the presence of such antibodies
had a deleterious effect on engraftment, particularly in the
setting of UCB transplantation. Although potentially effective
in controlling T cell responses, MSCs do not seem to elimi-
nate the deleterious effect of existing donor-speciﬁc anti-
HLA antibodies.
The decision to attempt the use of MSCs in this setting
was based on several reports that demonstrated intravenous
infusion of MSCs is safe and well tolerated [30,34e36]. In
addition, cotransplantation of autologous MSCs was associ-
ated with rapid hematopoietic recovery in patients with
breast cancer who underwent autologous SCT [29]. In a
prospective study of 46 patients with hematologic malig-
nancies, MSCs were cotransplanted with HSCs frommatched
sibling donors, and rapid engraftment of neutrophils and
platelets was reported [30]. Several studies have been un-
dertaken to investigate the effect of MSC cotransplantation
on HSC engraftment with mixed results [29,31,37,38].
Whereas most of these studies were done in adult patients
with malignancies, Macmillan et al. [31] described their
experience in pediatric patients undergoing UCB trans-
plantation for malignant disorders. In this small cohort of
high-risk leukemia patients, all assessable patients had
neutrophil engraftment at median of 19 days, whereas the
probability of platelet engraftment was 75% with a median of
53 days. No adverse effects of infusion of MSCs were noted
and no increase in the risk of infectious complications seen.
Additionally, no long-term effects of MSC infusion were
apparent at a median of 6.8 years of follow-up. Although
some studies have shown engraftment of MSCs in the bone
marrow [39,40], others did not ﬁnd engraftment of MSCs in
the marrow [35,41]. In our cohort of 6 patients, MSC
engraftment was not found in the bone marrow by short
tandem repeat analysis.
In addition, the immunosuppressive properties of MSCs
[42e46] have been exploited for treatment of GVHD
[47e49]. Although not the primary reason for their use in
this study, a secondary aim of the MSC infusion was to
reduce the incidence and severity of GVHD in such high-risk
patients. Two patients in this study developed grades II and
III acute GVHD, with the latter having steroid-refractory
GVHD that failed to respond to additional MSC infusions as
well. Still, the numbers of patients are too small to make any
conclusion on the effectiveness of MSC on the prevention
of GVHD.
Novel strategies are needed to overcome the engraftment
barrier that all studies have thus far observed in patients
with SCD. Moving forward, the presence of anti-HLA anti-
bodies should be taken into consideration to select appro-
priate HSC donors whether an unrelated adult donor or UCB
unit. However, the limited choice of donors in this particular
patient population makes this approach of selecting donors
difﬁcult and will pose another layer of challenge in ﬁnding
suitable donors. The presence of anti-HLA antibodies might
also help select which MSC “off the shelf” product to use
because it is possible that antibodies might eliminate MSCs
shortly after administration. Certainly, the development ofnovel strategies for overcoming the engraftment barrier are
generally needed but especially for this most challenging
patient population with SCD.
In addition to lack of consistent donor-derived hemato-
poietic recovery, viral reactivations and infections were
particularly problematic. In a recent report, patients treated
with MSCs for acute GVHD were shown to have high CMV
viral load and CMV-associated disease [50]. Certainly new
strategies are needed to speed immune recovery. However,
in patients treated with alemtuzumab, more intensive pro-
phylactic strategies and monitoring must be considered. One
such strategy includes use of intensive monitoring and
prophylaxis against CMV, such as the use of ganciclovir
during conditioning regimen followed by high-dose
acyclovir [51]. Additionally, cytotoxic T lymphocytes with
speciﬁcities toward adenovirus, Epstein-Barr virus, and CMV
have shown promise and are already being studied in clinical
trials [52,53]; cytotoxic T lymphocytes with speciﬁcity to-
ward HHV-6 are currently under investigation as well [54].
More generally, new strategies to enhance immune recovery
are needed for all patients undergoing HLA-mismatched
transplantation.
At this point, it is premature to believe that RIC or a
nonmyeloablative conditioning approach can provide reli-
able engraftment, particularly in the setting of a mismatched
transplant. Although combining low-dose conditioning with
any HSC source is the ultimate goal, perhaps a stepwise
approach should be considered, segregating the competency
of the graft from the conditioning regimen. In the interim,
RIC might best be limited to those patients who have
matched or closely matched grafts from an adult volunteer
donor from whom large numbers of HSCs can be collected,
with the use of more mismatched UCB with limited numbers
of HSCs limited to those who can tolerate fully myeloablative
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